CRVO
CervoMed Inc. NASDAQ Listed May 23, 2008$3.81
Mkt Cap $35.3M
52w Low $3.51
3.1% of range
52w High $13.13
50d MA $4.02
200d MA $6.92
P/E (TTM)
-1.2x
EV/EBITDA
-2.2x
P/B
1.8x
Debt/Equity
0.0x
ROE
-148.0%
P/FCF
-3.0x
RSI (14)
—
ATR (14)
—
Beta
-5.04
50d MA
$4.02
200d MA
$6.92
Avg Volume
75.3K
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CIK (SEC)
Phone
617-744-4400
20 Park Plaza · Boston, MA 02116 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | AMC | -0.79 | -0.88 | -11.4% | 4.25 | +0.5% | +1.4% | +6.6% | -0.2% | -0.5% | -5.4% | — |
| Nov 7, 2025 | AMC | -0.68 | -0.84 | -23.5% | 6.92 | -2.3% | -0.3% | +0.7% | +7.1% | +4.8% | +11.0% | — |
| Aug 8, 2025 | AMC | -0.57 | -0.70 | -22.8% | 9.85 | +1.1% | -3.6% | -4.6% | -2.1% | +3.5% | +2.7% | — |
| May 12, 2025 | AMC | -0.60 | -0.56 | +6.7% | 9.10 | -2.6% | -4.4% | -8.6% | -5.1% | -3.5% | -3.4% | — |
| Mar 17, 2025 | AMC | -0.67 | -0.80 | -19.4% | 9.05 | +7.5% | +3.2% | +3.5% | +27.7% | +57.9% | +18.3% | — |
| Nov 12, 2024 | AMC | -0.41 | -0.55 | -34.1% | 11.83 | +1.0% | -5.2% | -7.7% | -9.0% | -12.0% | -14.8% | — |
| Aug 9, 2024 | AMC | -0.24 | -0.27 | -12.5% | 11.28 | -3.9% | +7.5% | +33.0% | +51.1% | +51.1% | +61.9% | — |
| May 14, 2024 | AMC | -0.46 | -0.41 | +10.9% | 24.70 | +3.9% | +0.1% | -1.4% | -2.5% | -20.1% | -21.3% | — |
| Mar 25, 2024 | AMC | -0.29 | -0.38 | -31.0% | 21.08 | +2.5% | -1.4% | -6.9% | +10.5% | +7.7% | +5.1% | — |
| Nov 13, 2023 | AMC | -0.95 | -0.70 | +26.3% | 9.73 | +0.3% | -1.4% | +1.6% | +1.3% | +1.4% | +0.9% | — |
| Aug 8, 2023 | AMC | -2.90 | -1.04 | +64.1% | 4.89 | -3.1% | -3.7% | +7.8% | +6.5% | +12.1% | +20.9% | — |
| May 15, 2023 | AMC | -2.87 | -3.01 | -5.0% | 5.96 | +0.0% | -3.4% | -4.4% | -3.0% | +0.5% | +4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $3.96 | +0.5% | -2.3% | -1.5% | -3.0% | -5.8% | -7.4% |
| Apr 22 | D. Boral Capital | Maintains | Buy → Buy | — | $3.89 | $4.00 | +2.8% | +1.3% | -1.0% | -0.3% | -1.8% | -4.6% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $3.84 | $3.90 | +1.6% | +5.2% | +4.9% | -0.3% | +4.4% | +5.2% |
| Mar 19 | D. Boral Capital | Maintains | Buy → Buy | — | $4.24 | $4.23 | -0.2% | -0.2% | -5.2% | -5.2% | -7.5% | -4.7% |
| Mar 18 | Roth Capital | Maintains | Buy → Buy | — | $4.53 | $4.55 | +0.4% | -6.4% | -6.6% | -11.3% | -11.3% | -13.5% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $4.53 | $4.55 | +0.4% | -6.4% | -6.6% | -11.3% | -11.3% | -13.5% |
| Mar 16 | D. Boral Capital | Maintains | Buy → Buy | — | $4.25 | $4.27 | +0.5% | +1.4% | +6.6% | -0.2% | -0.5% | -5.4% |
| Mar 5 | Chardan Capital | Maintains | Buy → Buy | — | $4.02 | $4.07 | +1.2% | -0.2% | +2.2% | +12.9% | +20.9% | +10.0% |
| Mar 4 | D. Boral Capital | Maintains | Buy → Buy | — | $4.01 | $4.23 | +5.5% | +0.2% | +0.0% | +2.5% | +13.2% | +21.2% |
| Feb 18 | D. Boral Capital | Maintains | Buy → Buy | — | $4.54 | $4.75 | +4.6% | +8.6% | +15.2% | +2.0% | +2.2% | +5.5% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.99 | $8.10 | +1.4% | -1.1% | -4.9% | +1.6% | +5.4% | +6.1% |
| Dec 5 | D. Boral Capital | Maintains | Buy → Buy | — | $9.06 | $9.21 | +1.7% | -4.1% | -3.0% | -4.7% | -4.3% | -9.6% |
| Dec 2 | D. Boral Capital | Maintains | Buy → Buy | — | $9.22 | $9.32 | +1.1% | -10.8% | -10.2% | -1.7% | -5.7% | -4.7% |
| Nov 11 | D. Boral Capital | Maintains | Buy → Buy | — | $6.90 | $6.82 | -1.2% | +1.0% | +7.4% | +5.1% | +11.3% | +19.0% |
| Nov 5 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $7.02 | $7.54 | +7.4% | +4.6% | +3.8% | -1.4% | -1.7% | -0.7% |
| Nov 4 | D. Boral Capital | Maintains | Buy → Buy | — | $7.02 | $7.06 | +0.6% | +0.0% | +4.6% | +3.8% | -1.4% | -1.7% |
| Sep 8 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.51 | $10.51 | +0.0% | -4.9% | -4.9% | -9.4% | -12.5% | -15.8% |
| Aug 18 | D. Boral Capital | Maintains | Buy → Buy | — | $10.12 | $10.48 | +3.6% | -2.9% | -9.6% | -8.8% | -8.9% | -9.8% |
| Aug 12 | Roth Capital | Maintains | Buy → Buy | — | $9.50 | $9.64 | +1.5% | -1.1% | +1.5% | +7.3% | +6.5% | +3.5% |
| Aug 11 | D. Boral Capital | Maintains | Buy → Buy | — | $9.85 | $9.96 | +1.1% | -3.6% | -4.6% | -2.1% | +3.5% | +2.7% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.85 | $9.96 | +1.1% | -3.6% | -4.6% | -2.1% | +3.5% | +2.7% |
| Jul 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.67 | $8.95 | +3.2% | -2.9% | -2.0% | -4.8% | +1.8% | +7.6% |
| Jul 28 | D. Boral Capital | Maintains | Buy → Buy | — | $8.98 | $12.04 | +34.1% | -3.5% | -6.2% | -5.3% | -8.1% | -1.7% |
| Jul 25 | D. Boral Capital | Maintains | Buy → Buy | — | $8.05 | $8.01 | -0.5% | +11.6% | +7.7% | +4.6% | +5.6% | +2.5% |
| Jun 11 | D. Boral Capital | Maintains | Buy → Buy | — | $7.72 | $7.85 | +1.7% | -3.2% | -1.3% | -7.8% | -6.0% | -8.5% |
| May 13 | D. Boral Capital | Maintains | Buy → Buy | — | $9.10 | $8.86 | -2.6% | -4.4% | -8.6% | -5.1% | -3.5% | -3.4% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $8.49 | $8.77 | +3.3% | +7.2% | +2.5% | -2.0% | +1.8% | +3.4% |
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $8.85 | $8.80 | -0.6% | -12.9% | -4.0% | +7.1% | +3.4% | +12.8% |
| Mar 18 | Roth MKM | Maintains | Buy → Buy | — | $9.05 | $9.73 | +7.5% | +3.2% | +3.5% | +27.7% | +57.9% | +18.3% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $9.05 | $9.73 | +7.5% | +3.2% | +3.5% | +27.7% | +57.9% | +18.3% |
| Mar 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.05 | $9.73 | +7.5% | +3.2% | +3.5% | +27.7% | +57.9% | +18.3% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $6.44 | $7.07 | +9.8% | +40.5% | +45.0% | +45.5% | +79.5% | +121.9% |
| Mar 13 | Chardan Capital | Upgrade | Neutral → Buy | — | $6.17 | $7.79 | +26.3% | -6.2% | +4.4% | +46.7% | +51.4% | +51.9% |
| Mar 13 | Jones Trading | Upgrade | Hold → Buy | — | $6.17 | $7.79 | +26.3% | -6.2% | +4.4% | +46.7% | +51.4% | +51.9% |
| Mar 11 | D. Boral Capital | Maintains | Buy → Buy | — | $2.22 | $2.16 | -2.7% | +6.3% | +177.9% | +160.8% | +190.1% | +307.7% |
| Mar 11 | Roth MKM | Maintains | Buy → Buy | — | $2.22 | $2.16 | -2.7% | +6.3% | +177.9% | +160.8% | +190.1% | +307.7% |
| Feb 19 | D. Boral Capital | Upgrade | Hold → Buy | — | $2.23 | $2.28 | +2.2% | +3.1% | +4.5% | +2.2% | +0.4% | -2.7% |
| Dec 17 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.95 | $1.87 | -4.1% | -0.5% | +2.6% | +14.4% | +14.4% | +13.3% |
| Dec 11 | Chardan Capital | Downgrade | Buy → Neutral | — | $2.16 | $2.15 | -0.5% | -9.7% | -10.6% | -12.0% | -9.7% | -10.2% |
| Dec 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.16 | $2.15 | -0.5% | -9.7% | -10.6% | -12.0% | -9.7% | -10.2% |
| Dec 10 | Jones Trading | Downgrade | Buy → Hold | — | $10.25 | $2.53 | -75.3% | -78.9% | -81.0% | -81.2% | -81.5% | -81.0% |
| Dec 10 | D. Boral Capital | Downgrade | Buy → Hold | — | $10.25 | $2.53 | -75.3% | -78.9% | -81.0% | -81.2% | -81.5% | -81.0% |
| Nov 27 | D. Boral Capital | Maintains | Buy → Buy | — | $7.98 | $8.54 | +7.0% | +14.7% | +35.3% | +31.5% | +30.1% | +21.6% |
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $11.22 | $11.46 | +2.1% | -2.7% | -4.0% | -7.2% | -10.2% | -14.1% |
| Jul 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.85 | $14.93 | +0.5% | -3.2% | -5.5% | -3.0% | -6.5% | -12.5% |
| Apr 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $20.50 | $21.04 | +2.6% | +13.1% | +12.9% | +19.3% | +22.9% | +22.9% |
No insider trades available.
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed presented clinical data at the American Academy of Neurology conference, incorporating key findings into its SEC filing to highlight potentially significant trial results for investors.
Apr 22
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CervoMed's presentation of positive neflamapimod clinical findings and finalized Phase 3 trial design signals advancement toward a potentially valuable dementia treatment, which could drive stock appreciation if trial results prove successful.
Apr 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Crescent Robotics disclosed information via Regulation FD that isn't legally binding and won't affect existing SEC filings, so investors should disregard this as non-material disclosure.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CRVO's biomarker analysis showing stronger treatment effects in lower tau patients could support a narrower, higher-probability approval pathway, potentially de-risking future regulatory decisions and improving stock valuation.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Cerevel Therapeutics disclosed material non-public information to select parties, potentially signaling upcoming news that could impact stock valuation before public announcement.
Mar 17
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed's incorporation of its March 4, 2026 press release details into an 8-K filing indicates a material corporate event requiring SEC disclosure, though the specific announcement details require reviewing the referenced press release.
Mar 4
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed Inc. disclosed material information through a February 18, 2026 press release, incorporated into this 8-K filing, though specific details require reviewing the referenced press release for investor impact assessment.
Feb 18
Data updated apr 25, 2026 3:24am
· Source: massive.com